Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T17:13:06.450Z.
Consensus retrieved: 2026-10-06T12:36:28.771Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T17:13:06.450Z.
Quote observation: 2026-10-06T17:10:21.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 12822cf5764c24a0ef00c724f2a960962c8ab94682162e48d6be38065653aaef
Forward PE Ratio (N/A) = Dated Quote Price ($9.86) / Consensus Forward EPS ($-0.96)
FORWARD PE RATIO
N/A
ImmunityBio, Inc.
Market Cap
$10.33B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| ImmunityBio, Inc. (IBRX) | $10.33B | N/A |
| Globus Medical, Inc. (GMED)vs › | $10.41B | 15.43 |
| Align Technology, Inc. (ALGN)vs › | $10.19B | 12.60 |
| The Ensign Group, Inc. (ENSG)vs › | $10.13B | 22.29 |
| Repligen Corporation (RGEN)vs › | $10.08B | 86.77 |
| Universal Health Services, Inc. (UHS)vs › | $10.65B | 7.79 |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $10.03B | 38.23 |
| Molina Healthcare, Inc. (MOH)vs › | $10.01B | N/A |
| BioMarin Pharmaceutical Inc. (BMRN)vs › | $10.82B | N/A |
| The Cooper Companies, Inc. (COO)vs › | $10.98B | 12.40 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $9.86, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.96 | $-0.99 – $-0.92 | 2 | n/m |
| 2027-12-31 | $-0.14 | $-0.35 – $0.07 | 2 | n/m |
| 2028-12-31 | $0.42 | $0.30 – $0.54 | 2 | 23.5x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
